| Literature DB >> 15018621 |
Steven Neese1, Linda La Grange, Elisharose Trujillo, David Romero.
Abstract
BACKGROUND: Using a rat model we have found that the bioflavonoid silymarin (SY) ameliorates some of the negative consequences of in utero exposure to ethanol (EtOH). In the current study our aim was to determine if spatial working memory (SWM) was impaired in offspring whose mothers were maintained on a liquid diet containing EtOH during different gestational weeks. We also determined if SWM was altered with a concomitant administration of SY with EtOH during specific gestational weeks.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15018621 PMCID: PMC356922 DOI: 10.1186/1472-6882-4-4
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Experimental Group Treatment Per Week Over the Three-Week Gestation Period.
| 1 | EtOH 1–7 | EtOH | LD | LD |
| 2 | EtOH 8–14 | LD | EtOH | LD |
| 3 | EtOH 15–21 | LD | LD | EtOH |
| 4 | EtOH/SY 1–7 | EtOH/SY | LD | LD |
| 5 | EtOH/SY 8–14 | LD | EtOH/SY | LD |
| 6 | EtOH/SY 15–21 | LD | LD | EtOH/SY |
| 7 | LD/SY 1–7 | LD/SY | LD | LD |
| 8 | LD/SY 8–14 | LD | LD/SY | LD |
| 9 | LD/SY 15–21 | LD | LD | LD/SY |
| 10 | EtOH Full | EtOH | EtOH | EtOH |
| 11 | EtOH/SY Full | EtOH/SY | EtOH/SY | EtOH/SY |
| 12 | LD/SY Full | LD/SY | LD/SY | LD/SY |
| 13 | LD Full | LD | LD | LD |
| 14 | Chow | Chow | Chow | Chow |
Female Data on RAM Performance and Mistakes for EtOH weekly treatment groups.
| RAM (days) | Mistakes | |||
| M | SD | M | SD | |
| EtOH 1–7 | 3.88 | 2.23 | 15.13 | 10.93 |
| EtOH 8–14 | 4.13 | 2.59 | 17.25 | 8.41 |
| EtOH 15–21 | 6.75* | 2.43 | 13.75 | 7.17 |
*p < 0.05
Female Data for RAM Performance and Mistakes for selected full treatment groups.
| RAM (days) | Mistakes | |||
| M | SD | M | SD | |
| EtOH/SY full | 2.50 | 1.77 | 10.25 | 6.48 |
| EtOH full | 6.13* | 3.40 | 19.25* | 12.35 |
| LD full | 5.13 | 2.48 | 9.38 | 7.03 |
*p < 0.05
Female Weight Data for EtOH weekly treatment groups.
| Birth (g) | Weaning (g) | RAM (g) | Perfusion (g) | TBW (g) | ||||||
| M | SD | M | SD | M | SD | M | SD | M | SD | |
| EtOH 1–7 | 4.65 | 0.14 | 29.88 | 2.80 | 88.86 | 10.72 | 154.22 | 13.94 | 1.63 | 0.05 |
| EtOH 8–14 | 4.76 | 0.44 | 30.84 | 3.80 | 92.38 | 8.27 | 157.87 | 8.65 | 1.64 | 0.03 |
| EtOH 15–21 | 5.14* | 0.32 | 25.74* | 4.78 | 86.49* | 14.49 | 139.79* | 19.89 | 1.57* | 0.10 |
*p < 0.05
Female Weight Data for selected EtOH/SY and LD/SY weekly treatment groups.
| Birth (g) | Weaning (g) | RAM (g) | Perfusion (g) | |||||
| M | SD | M | SD | M | SD | M | SD | |
| EtOH/SY 1–7 | 4.11 | 0.57 | 26.06 | 3.36 | 85.65 | 7.59 | 149.18 | 6.56 |
| LD/SY 1–7 | 4.49* | 0.40 | 25.63 | 3.76 | 92.54 | 9.28 | 140.30 | 12.47 |
| EtOH/SY 8–14 | 4.75 | 0.38 | 27.25 | 6.74 | 82.19 | 10.61 | 155.34 | 7.35 |
| LD/SY 8–14 | 5.12* | 0.14 | 31.44* | 5.78 | 94.36* | 4.96 | 151.28 | 9.00 |
*p < 0.05
Male Weight Data for EtOH weekly treatment groups.
| Birth (g) | Weaning (g) | RAM (g) | Perfusion (g) | |||||
| M | SD | M | SD | M | SD | M | SD | |
| EtOH 1–7 | 4.65 | 0.14 | 32.15 | 1.26 | 117.51 | 10.05 | 221.46 | 15.00 |
| EtOH 8–14 | 5.08 | 0.40 | 35.32* | 6.73 | 109.47 | 32.03 | 234.51 | 20.12 |
| EtOH 15–21 | 5.29* | 0.32 | 30.83 | 2.85 | 116.74 | 16.44 | 224.72 | 12.91 |
*p < 0.05